Dr. Reddy's Laboratories Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Dr. Reddy's Laboratories ha aumentado sus beneficios a una tasa media anual de 23.6%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 1.7% anual. Los ingresos han ido creciendo a una tasa media de 11.8% al año. La rentabilidad financiera de Dr. Reddy's Laboratories es de 19.5%, y sus márgenes netos son de 19.2%.

Información clave

23.6%

Tasa de crecimiento de los beneficios

23.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	6.0%
Tasa de crecimiento de los ingresos	11.8%
Rentabilidad financiera	19.5%
Margen neto	19.2%
Próxima actualización de resultados	07 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements

Nov 29

Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook

Oct 27

Dr. Reddy's prepare to file for Rituxan biosimilar in US, EU as trials completed

Jan 20

Dr. Reddy's Needs Time For Generics Sales To Replace Sputnik Revenue

Nov 07

Dr. Reddy's GAAP EPS of $0.90, revenue of $660M misses by $12.78M

Jul 28

Dr. Reddy's launches generic drugs for allergies in US

Jul 22

Dr. Reddy's, EQRx team up to develop drugs for cancer, immune-inflammatory diseases

Jul 05

Dr. Reddy's in talks to bring single-dose Sputnik Light vaccine in India

May 31

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Dr. Reddy's Laboratories. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NYSE:RDY Ingresos, gastos y beneficios (INR Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	271,302	52,206	74,717	21,362
30 Sep 23	266,854	50,888	72,470	20,618
30 Jun 23	261,109	47,216	70,235	20,040
31 Mar 23	245,879	45,067	68,026	19,381
31 Dec 22	237,279	36,350	65,708	18,341
30 Sep 22	222,776	30,944	63,138	17,679
30 Jun 22	217,351	29,736	62,529	17,273
31 Mar 22	214,391	23,568	62,081	17,482
31 Dec 21	207,307	26,317	60,717	17,250
30 Sep 21	203,406	19,450	59,693	17,199
30 Jun 21	194,741	17,153	56,849	17,095
31 Mar 21	189,722	17,238	54,650	16,541
31 Dec 20	186,756	21,256	52,457	16,637
30 Sep 20	181,298	15,361	50,740	16,478
30 Jun 20	180,340	18,663	50,850	15,781
31 Mar 20	174,600	19,498	50,129	15,410
31 Dec 19	170,448	16,200	50,246	14,882
30 Sep 19	165,110	26,749	49,484	14,601
30 Jun 19	155,079	20,862	48,639	15,059
31 Mar 19	153,851	18,795	48,680	15,607
31 Dec 18	149,034	17,473	48,400	16,293
30 Sep 18	148,594	15,965	48,540	17,292
30 Jun 18	145,903	13,776	47,200	17,347
31 Mar 18	141,855	9,806	46,857	18,265
31 Dec 17	141,827	9,909	45,370	18,458
30 Sep 17	140,588	11,266	44,663	18,747
30 Jun 17	140,907	11,367	45,405	19,786
31 Mar 17	139,870	12,039	46,300	19,513
31 Dec 16	141,269	9,660	46,961	19,718
30 Sep 16	144,127	10,751	47,659	18,857
30 Jun 16	148,410	15,019	46,943	18,116
31 Mar 16	153,866	20,013	45,641	17,701
31 Dec 15	155,850	24,456	44,152	18,100
30 Sep 15	154,602	24,409	43,264	18,321
30 Jun 15	150,592	22,932	42,879	17,961
31 Mar 15	147,360	22,179	42,076	17,329
31 Dec 14	143,474	21,806	42,810	16,289
30 Sep 14	140,380	22,247	42,102	14,952
30 Jun 14	138,076	23,409	41,165	13,847
31 Mar 14	132,170	21,515	38,783	12,402
31 Dec 13	130,043	22,409	37,695	10,852
30 Sep 13	123,357	20,005	35,823	9,898
30 Jun 13	118,591	17,027	34,101	8,648

Ingresos de calidad: RDY tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (19.2%) de RDY son superiores a los del año pasado (15.3%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: En los últimos 5 años, los beneficios de lRDY han crecido significativamente en un 23.6% al año.

Acelerando crecimiento: El crecimiento de los beneficios de RDY en el último año (43.6%) supera su media de 5 años (23.6% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de RDY en el último año (43.6%) superó al de la industria Pharmaceuticals -6.8%.

Dr. Reddy's Laboratories Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Información clave

Actualizaciones de resultados anteriores recientes

Dr. Reddy's Laboratories Limited to Report Q4, 2024 Results on May 07, 2024

Dr. Reddy's Laboratories Limited to Report Q3, 2024 Results on Jan 30, 2024

Dr. Reddy's Laboratories Limited to Report Q2, 2024 Results on Oct 27, 2023

Dr. Reddy's Laboratories Limited to Report Q1, 2024 Results on Jul 26, 2023

Dr. Reddy's Laboratories Limited Reports Impairment Charges for the Fourth Quarter Ended March 31, 2023

Dr. Reddy's Laboratories Limited to Report Q3, 2023 Results on Jan 25, 2023

Recent updates

Dr. Reddy's Laboratories Limited Announces Executive Changes

Dr. Reddy's Laboratories Limited to Report Q4, 2024 Results on May 07, 2024

Walgreen Co., Kroger Specialty Pharmacy, Inc. and CVS Pharmacy, Inc. File Complaint Against Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Dr. Reddy's Laboratories Limited Appoints Sanjiv Mehta as A Non-Executive Independent Member of the Board

Dr Reddy's Laboratories Reportedly Eyes Mega Brand in UK

Dr. Reddy's Laboratories Limited Announces Change in Management

Dr. Reddy's Laboratories Limited Announces Appointment of Sanjiv Mehta as Additional Director

Dr. Reddy's Laboratories Limited to Report Q3, 2024 Results on Jan 30, 2024

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed GMP and Pre-Approval Inspection

Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements

Dr. Reddy's Laboratories Ltd. Announces the Roll-Out of Nerivio in India

Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook

Dr. Reddy's Laboratories Limited to Report Q2, 2024 Results on Oct 27, 2023

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Dr. Reddy's: Growth Supported By New Labels, Profitability

Dr. Reddy's Laboratories Ltd. Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S

Dr. Reddy's Laboratories Limited Announces Resignation of Mukesh Rathi as Chief Information Officer

Dr. Reddy's Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2023

Dr. Reddy's Laboratories Limited Announces Management Changes

Dr. Reddy's Laboratories Limited Announces Its Proposed Rituximab Biosimilar Application Acceptance for Review by USFDA, EMA and MHRA

Dr. Reddy's Laboratories Limited to Report Q1, 2024 Results on Jul 26, 2023

Dr. Reddy's Laboratories: Unpacking The Critical Factors, Reiterate Buy

Dr. Reddy's Laboratories Limited Completes Phase I Study (IV Route) of DRL_TC

Dr. Reddy's Laboratories Limited Reports Impairment Charges for the Fourth Quarter Ended March 31, 2023

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 27, 2023

Dr. Reddy's Laboratories Limited Announces the Launch of Regadenoson Injection 0.4 Mg/5 Ml in the U.S

Dr. Reddy's Laboratories: Positive Q3 Results, Growth Supportive Of Buy

Dr. Reddy's Laboratories Limited Announces the Launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

Dr. Reddy's Laboratories Limited Completes Full Set of Clinical Studies of Its Rituximab Biosimilar for Filing in the U.S., Europe

Dr. Reddy's prepare to file for Rituxan biosimilar in US, EU as trials completed

Dr. Reddy’S Launches In-House Palbociclib (Primcyv®) to Widen Access to High-Quality Breast Cancer Drug

Dr. Reddy's Laboratories Limited Announces Resignation of Allan Grant Oberman as an Independent Director

Dr. Reddy's Laboratories Provides Updates on Litigation

Dr. Reddy's Laboratories Limited to Report Q3, 2023 Results on Jan 25, 2023

Dr. Reddy s Laboratories Ltd. Announces Tocilizumab Biosimilar Candidate, DRL_TC, Successfully Met Its Primary and Secondary Endpoints in A Phase 1 Study

Dr. Reddy's Needs Time For Generics Sales To Replace Sputnik Revenue

Dr. Reddy's Laboratories Limited Announces Change in Directorate

Dr. Reddy's Laboratories Limited Appoints Mr. Arun Madhavan Kumar as an Independent Director

Dr. Reddy's Laboratories Limited to Report Q2, 2023 Results on Oct 28, 2022

Dr. Reddy's Laboratories Limited Informs Bruce L A Carter, Independent Director of the Company Has Ceased to Be A Director

Dr. Reddy's Laboratories Limited Appoints Arun Madhavan Kumar as an Independent Additional Director

Dr. Reddy's GAAP EPS of $0.90, revenue of $660M misses by $12.78M

Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection, 3.5 Mg Single-Dose Vial in the U.S. Market

Dr. Reddy's Laboratories Limited Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market

Dr. Reddy's launches generic drugs for allergies in US

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed Pre-Approval Inspection At Formulations Manufacturing Facility FTO 11 in Srikakulam, Andhra Pradesh

Dr. Reddy's, EQRx team up to develop drugs for cancer, immune-inflammatory diseases

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Portfolio of four paediatric brands from Dr. Reddy's Laboratories Limited (BSE:500124) for INR 98 million.

Dr. Reddy's Laboratories Limited to Report Q1, 2023 Results on Jul 28, 2022

Dr. Reddy's Laboratories Limited Announces Settlement Agreement with Respect to Buprenorphine and Naloxone Sublingual Film

Dr. Reddy's Laboratories Announces the Launch of the Generic Version of Nexavar (Sorafenib) Tablets, USP, 200 Mg in the U.S. Market

Dr. Reddy’S Laboratories Ltd. Announces the Launch of Pemetrexed for Injection, 100 Mg and 500 Mg Single-Dose Vials, the Generic Equivalent of Alimta® (Pemetrexed for Injection) in the U.S. Market Approved by the U.S. Food and Drug Administration

Torrent Pharmaceuticals Limited (BSE:500420) entered into an agreement to acquire Styptovit-E, Finast, Finast-T and Dynapress brands from Dr. Reddy's Laboratories Limited (BSE:500124).

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch Ketorolac Tromethamine Tablets USP, 10 MG in the U.S. Market

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch Ketorolac Tromethamine Tablets USP, 10 MG in the U.S. Market

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 29, 2022

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jun 29, 2022

Dr. Reddy's Laboratories Limited Launches Posaconazole Delayed-Release Tablets in the U.S. Market

Torrent, JB Chemicals Reportedly in Final Race to Acquire Curatio Healthcare

Dr. Reddy's Laboratories Limited Announces the Launch of Methylprednisolone Sodium Succinate for Injection, USP in the U.S. Market

Dr. Reddy's Laboratories Limited to Report Q4, 2022 Results on May 19, 2022

Dr. Reddy's Laboratories Limited to Report Q4, 2022 Results on May 19, 2022

Dr Reddy's, Biocon Reportedly Among 6 Drug Companies in Race for Curatio

Alium JSC entered into agreement to acquire Two anti-bacterial brand Ciprolet and Levolet from Dr. Reddy's Laboratories Limited (BSE:500124).

Dr. Reddy's Laboratories Announces the Launch of Its Authorized Generic Version of VASOSTRICT Vials in the U.S. Market

Dr. Reddy's Laboratories Limited Announces DCGI Approval to the Single-Shot Sputnik Light Vaccine in India

Desglose de ingresos y gastos
Beta